Search Within

Michael John Mauro

Formats
  1. Meeting Abstract (188)
  2. Journal Article (67)
  3. Review (8)
  4. Correspondence (4)
  5. Research Letter (3)
  6. Book Section (2)
  7. Editorial (2)
  8. Guidelines (2)
Groups
  1. Adult Leukemia (276)
  2. Center for Hematologic Malignancies (276)
  3. Department of Medicine (276)
  4. Hematologic Malignancies, Division of (276)
  5. Biostatistics Service (10)
  6. Epidemiology and Biostatistics (10)

More Groups

People
  1. Raajit Rampal (12)
  2. Ellin Berman (8)
  3. Eytan Stein (8)
  4. Martin Tallman (7)
  5. Amber King (6)
  6. Andriy Derkach (6)

More People

Years
  1. 2025 (7)
  2. 2024 (17)
  3. 2023 (26)
  4. 2022 (33)
  5. 2021 (21)
  6. 2020 (26)

More Years

Publications
  1. Blood (97)
  2. Clinical Lymphoma, Myeloma and Leukemia (44)
  3. Journal of Clinical Oncology (22)
  4. Haematologica (21)
  5. Leukemia (12)
  6. American Journal of Hematology (8)

More Publications

Publishers
  1. American Society of Hematology (101)
  2. Elsevier Inc. (47)
  3. American Society of Clinical Oncology (22)
  4. Ferrata Storti Foundation (21)
  5. Nature Publishing Group (13)
  6. John Wiley & Sons (8)

More Publishers

Results (276)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Characteristics of ponatinib (PON) therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) patients (pts) in real-world (RW) clinical practice compared to the PACE trial
    Meeting Abstract

    Mauro, M. J.; McGarry, L.; Yang, M.; Lustgarten, S.; Huang, H.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Comparison of PACE clinical trial versus real-world (RW) ponatinib (PON) prescribing and duration of therapy (DOT) in US chronic-phase chronic myeloid leukemia (CP-CML) patients (pts)
    Meeting Abstract

    Mauro, M. J.; McGarry, L.; Yang, M.; Lustgarten, S.; Huang, H.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Expanded phase 1 study of ABL001, a potent, allosteric inhibitor of BCR-ABL, reveals significant and durable responses in patients with CML-chronic phase with failure of prior TKI therapy
    Meeting Abstract

    Hughes, T. P.; Goh, Y. T.; Ottmann, O. G.; Minami, H.; Rea, D.; Lang, F.; Mauro, M. J.; DeAngelo, D. J.; Talpaz, M.; Hochhaus, A.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Tyrosine kinase inhibitor (TKI) switching patterns during the first 12 months in simplicity, an observational study of chronic-phase chronic myeloid leukemia (CP-CML) patients (Pts) in routine clinical practice
    Meeting Abstract

    Goldberg, S.; Michallet, M.; Hehlmann, R.; Zyczynski, T.; Foreman, A.; Calimlim, B.; Paquette, R.; Simonsson, B.; Gambacorti, C.; Cortes, J. E.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Treatment-free remission (TFR) in patients with chronic phase chronic myeloid leukemia (CML-CP) and in stable deep molecular response (DMR) to dasatinib - The DASFREE study
    Meeting Abstract

    Shah, N. P.; Paquette, R.; Müller, M. C.; Saussele, S.; Garcìa-Gutiérrez, V.; Jiménez-Velasco, A.; Nicolini, F. E.; Mauro, M. J.; Mahon, F. X.; Rea, D.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • ENESTgoal treatment-free remission study: Updated preliminary results and digital polymerase chain reaction analysis in patients with chronic myeloid leukemia in chronic phase who switched from imatinib to nilotinib
    Meeting Abstract

    Ritchie, E. K.; Catchatourian, R.; Klisovic, R. B.; Pinilla-Ibarz, J.; Deininger, M. W.; Erba, H. P.; Radich, J. P.; Savona, M. R.; Dautaj, I.; Wolff, J.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Ponatinib in chronic-phase chronic myeloid leukemia patients: Final report from a phase 1 trial
    Meeting Abstract

    Mauro, M. J.; Cortes, J. E.; Kantarjian, H. M.; Shah, N. P.; Bixby, D. L.; Flinn, I. W.; O'Hare, T.; Rivera, V. M.; Lustgarten, S.; Santillana, S.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Predictors of ponatinib therapy duration among real-world chronic phase chronic myeloid leukemia (CP-CML) patients in the US
    Meeting Abstract

    Mauro, M. J.; McGarry, L. J.; Lustgarten, S.; Huang, H.
    Blood (2016)

    Fulltext@MSK | Save
  • Treatment-related infections and risk factors in patients with myeloproliferative neoplasms treated with ruxolitinib
    Meeting Abstract

    King, A. C.; Hsu, M.; Mauro, M. J.; Rampal, R. K.
    Blood (2016)

    Fulltext@MSK | Save
  • Long-term follow-up of the efficacy and safety of ponatinib in Philadelphia chromosome-positive leukemia patients with the T315I mutation
    Meeting Abstract

    Jabbour, E. J.; Cortes, J. E.; Talpaz, M.; Baccarani, M.; Mauro, M. J.; Hochhaus, A.; Hughes, T. P.; Guilhot, F.; Deininger, M. W.; Shah, N.; more...
    Blood (2016)

    Fulltext@MSK | Save